<DOC>
	<DOCNO>NCT02833350</DOCNO>
	<brief_summary>This multicenter , Phase II , randomize , double-blind , placebo-controlled , active comparator ( Cohort 1 ) , parallel-group , dose-ranging study evaluate efficacy safety GDC-0853 participant moderate severe active RA inadequate response previous methotrexate therapy ( Cohort 1 ) methotrexate tumor necrosis factor ( TNF ) therapy ( Cohort 2 ) .</brief_summary>
	<brief_title>Safety Efficacy Study GDC-0853 Compared With Placebo Adalimumab Participants With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Have diagnosis adultonset RA define 2010 American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) Classification Criteria RA RA disease activity joint count laboratory marker inflammation : great equal ( &gt; = ) 6 tender/painful joint motion ( 68 joint count ) &gt; = 6 swollen joint ( 66 joint count ) screen Day 1 ( randomization ) For methotrexateinadequate response ( IR ) participant : must inadequate response methotrexate For TNFIR participant : must inadequate response 1 2 TNF inhibitor History current inflammatory joint disease RA systemic autoimmune disorder For methotrexateIR participant : History treatment TNF inhibitor , include biosimilar equivalent For participant : Previous treatment nonTNF inhibitor biologic diseasemodifying antirheumatic drug ( DMARDs ) ( include biosimilar equivalent ) , tofacitinib , Janus kinase inhibitor ( ) , alkylating agent Evidence serious uncontrolled concomitant cardiac , neurologic , pulmonary , renal , hepatic , endocrine , metabolic , gastrointestinal ( GI ) disease Evidence chronic and/or active hepatitis B C Women pregnant , nursing ( breast feeding ) , intend become pregnant study within 60 day completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>